Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

The Role of Health Care Providers on Encouraging Adalimumab Biosimilar Use

May 3rd 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice.

The Top 5 Biosimilar Articles for the Week of April 29

May 3rd 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 29, 2024.

Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars

May 2nd 2024

By Skylar Jeremias

Article

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.

FDA Approves High-Concentration Cyltezo

May 1st 2024

By Skylar Jeremias

Article

The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it the second high-concentration adalimumab biosimilar to have an interchangeability designation.

Biosimilars Policy Roundup: April 2024

May 1st 2024

By Skylar Jeremias

Article

April brought 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.

Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability

April 30th 2024

By Skylar Jeremias

Article

During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.

Clinical Experience With Initiating Adalimumab Biosimilars

April 29th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars.

Switching From Adalimumab to a Biosimilar

April 29th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.

FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi

April 29th 2024

By Skylar Jeremias

Article

The approval marks the sixth for a biosimilar referencing Herceptin (trastuzumab) for the treatment of HER2-positive breast and gastric cancers.

Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar

April 29th 2024

By Skylar Jeremias

Article

The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.